drugset / Trial / NCT04732169

Cannabidiol for Treatment Resistant Depression

NCT04732169

RandomizedCrossoverTriple-blindTreatment

Summary

With this study, the investigators will address the following scientific aims: 1. Demonstrate the antidepressant effects of CBD in human adults with treatment refractory MDD as measured by standard rating scales. 2. Confirm CBD's safety profile in human adult patients with MDD.

Timeline

Start
2021-07-01
Primary completion
2021-07-09
Completion
2021-07-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cannabidiol Other / unclassified 500 mg Oral

Indications

No indication recorded.